Huzhou Haiwang Health Industry Development Co., Ltd.

The main purpose of the study is to study the time course of oseltamivir and its active metabolite oseltamivir carboxylic acid in the body after a single oral dose of oseltamivir phosphate capsules in healthy Chinese subjects in the fasting and postprandial states, using oseltamivir phosphate capsules (specification: 75 mg) produced by Delpharm Milano S.r.l., the original research and marketing authorization holder, Roche Registration Ltd., and packaged by Shanghai Roche Pharmaceuticals as the reference preparation, and oseltamivir phosphate capsules (specification: 75 mg) produced by Huzhou Haiwang Health Industry Development Co., Ltd. as the test preparation, to calculate their pharmacokinetic parameters, compare the relative bioavailability of the two preparations, and evaluate the human bioequivalence of the two. Secondary purpose: to observe and evaluate the relative bioavailability of the single oral dose of the test preparation after fasting and postprandial administration, and evaluate the human bioequivalence of the two.